文献速递母胎医学产科

颈项透明层3.0至3.4毫米胎儿的临床显著染色体微阵列分析结果风险

Risk of Clinically Significant Chromosomal Microarray Analysis Findings in Fetuses With Nuchal Translucency From 3.0 mm Through 3.4 mm.
PubMed 文献 · Obstet Gynecol · 2021-01-01

该回顾性队列研究基于以色列卫生部数据库,分析619例孤立性颈项透明层3.0-3.4毫米且超声无异常的胎儿染色体微阵列分析结果,发现临床显著拷贝数变异率为4.7%,显著高于对照组(相对风险3.3,95%CI 2.6-7.2)。无创产前检测针对五种常见染色体非整倍体会漏检41.4%的异常拷贝数变异。

要点

  • 颈项透明层3.0-3.4毫米胎儿临床显著染色体微阵列异常率为4.7%,风险显著增高。
  • 无创产前检测针对五种常见非整倍体会漏检41.4%的异常拷贝数变异。
  • 全基因组无创产前检测或传统核型分析可能漏检1.5%(9/619)的异常发现。

核心结论

  • 颈项透明层3.1-3.4毫米胎儿的染色体微阵列分析异常率显著高于超声正常胎儿。

研究设计与样本

  • 回顾性队列研究,纳入619例因颈项透明层3.0-3.4毫米且无超声异常而行染色体微阵列分析的胎儿,对照为2752例超声正常且颈项透明层小于3.0毫米的胎儿。

主要发现

  • 619例中29例(4.7%)存在临床显著拷贝数变异,相对风险3.3(95%CI 2.6-7.2)。
  • 无创产前检测针对五种常见染色体非整倍体会漏检41.4%的异常拷贝数变异,占总体1.9%(1/52)。
  • 全基因组无创产前检测或传统核型分析可能漏检9/619(1.5%)的异常发现(1/69)。

临床怎么用

  • 对颈项透明层3.1-3.4毫米且超声无异常的胎儿,应告知染色体微阵列分析可提高临床显著拷贝数变异的检出。
  • 咨询时需说明无创产前检测针对常见非整倍体的局限性,可能漏检部分异常拷贝数变异。

局限性

  • 回顾性设计,对照来自既往发表数据,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the risk of clinically significant chromosomal microarray analysis findings in fetuses with nuchal translucency from 3.0-3.4 mm. In addition, we aimed to define the yield of noninvasive prenatal testing (NIPT) in such pregnancies. METHODS: This retrospective cohort study included results of all chromosomal microarray analysis tests performed owing to a nuchal translucency measurement from 3.0-3.4 mm, without ultrasonographic anomalies, retrieved from the Israeli Ministry of Health computerized database. Rates of clinically significant (pathogenic and likely pathogenic) microarray findings were compared with a previously published local control population, encompassing 2,752 fetuses with normal ultrasound findings and nuchal translucency less than 3.0 mm. RESULTS: Overall, 619 chromosomal microarray analyses were performed owing to isolated nuchal translucency from 3.0-3.4 mm. Of these, 29 (4.7%) cases had clinically significant copy number variants, a significantly higher risk compared with control-group pregnancies (relative risk 3.3, 95% CI 2.6-7.2). Divided by tenths of millimeters, the risk for abnormal chromosomal microarray analysis findings remained significantly increased, except for the subgroup of 198 fetuses with nuchal translucency measurements of 3.0 mm. Noninvasive prenatal testing for the five common chromosome aneuploidies would have missed 41.4% of the abnormal copy number variants-1.9% of overall cases, or 1 in 52 fetuses with nuchal translucency from 3-3.4 mm. Genome-wide NIPT, as well as traditional karyotyping, could have missed an abnormal finding in 9 of 619 (1.5%), or 1 in 69 fetuses. CONCLUSION: Our outcomes show that the rate of abnormal chromosomal microarray analysis findings in fetuses with nuchal translucency from 3.1-3.4 mm is significantly higher compared with fetuses with normal ultrasound findings.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sagi-Dain L, Singer A, Ben Shachar S, et al. Risk of Clinically Significant Chromosomal Microarray Analysis Findings in Fetuses With Nuchal Translucency From 3.0 mm Through 3.4 mm. Obstet Gynecol. 2021. PMID: 33278279. doi:10.1097/AOG.0000000000004195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。